Enzyme kinetics and biochemical analysis of ImiS, the metallo-β-lactamase from Aeromonas sobria 163a

Competitive Inhibitors of the CphA Metallo- -Lactamase from Aeromonas hydrophila

Competitive Inhibitors of the CphA Metallo-Lactamase from Aeromonas hydrophila L. E. Horsfall,† G. Garau,† B. M. R. Liénard, O. Dideberg, C. J. Schofield, J. M. Frère, and M. Galleni* Centre d’Ingéniérie des Protéines, Université de Liège, Allée de 6 Aout B6, Sart-Tilman, Liège, Belgium; Institut de Biologie Structurale Jean-Pierre Ebel (CNRS/CEA/UJF), 41 Rue J. Horowitz, Grenoble 38100, France...

Biochemical characterization of the POM-1 metallo-β-lactamase from Pseudomonas otitidis.

The POM-1 metallo-β-lactamase is a subclass B3 resident enzyme produced by Pseudomonas otitidis, a pathogen causing otic infections. The enzyme was overproduced in Escherichia coli BL21(DE3), purified by chromatography, and subjected to structural and functional analysis. The purified POM-1 is a tetrameric enzyme of broad substrate specificity with higher catalytic activities with penicillins a...

Identification of the first VIM metallo - β - lactamase producing multiresistant Aeromonas 1 hydrophila strain 2 3 Running title : VIM metallo - β - lactamase producing A . hydrophila 4 5

New Delhi Metallo-β-Lactamase, Ontario, Canada

To the Editor: The New Delhi metallo-β-lactamase (NDM-1) was fi rst characterized in 2009 from Kleb-siella pneumoniae and Escherichia coli isolated from a patient in Sweden who had received medical care in New Delhi, India (1). Further studies have shown broad dissemination of this β-lactamase gene (bla NDM-1) in India, Pakistan, Bangladesh, and the United Kingdom (2). Additional isolates have ...

New Delhi Metallo-β-Lactamase from Traveler Returning to Canada1

An Escherichia coli isolate with New Delhi metallo-beta-lactamase was isolated from a patient with pyelonephritis and prostatitis who returned to Canada after recent hospitalization in India. The patient was successfully treated with ertapenem and fosfomycin. This patient highlights the role of international travel in the spread of antimicrobial drug resistance and blaNDM-1.